TL;DR
Vesalius Longevity Labs raised nearly $6.5 million in a private placement led by an investor group organized by Equinox Group Chairman Harvey Spevak. The company says it will use the proceeds to expand its sales team, enter new markets and grow its platform linking licensed healthcare providers with longevity-related services. The financing terms include warrants, while the company’s plans and the investment’s impact remain to be seen.
Vesalius Longevity Labs has raised nearly $6.5 million in a private placement led by an investor group organized by Harvey Spevak, chairman of Equinox Group. The publicly traded company said it plans to use the financing to expand its sales team, enter new markets and grow its platform connecting licensed healthcare providers with peptide therapies and other longevity-focused offerings.
Get wellness gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
According to Athletech News, Vesalius sold approximately 6.2 million units at $1.05 each, generating nearly $6.5 million in gross proceeds. The source describes the transaction as completed. It does not provide a breakdown of expenses or specify how much of the gross amount will be available for each planned use.
The units include warrants that allow investors to purchase additional shares at $2.25 per share during the next two years. Those warrants give investors the option, but not the obligation, to buy shares at that price. The report does not say whether any warrants have been exercised or how many shares could be issued if they are.
Vesalius describes its business as a provider-focused platform spanning peptides, biologics, preventive healthcare and performance optimization. Its model connects healthcare providers with telehealth infrastructure, product fulfillment and regenerative-health offerings. The company’s stock trades on the Canadian Securities Exchange under the ticker SE; the report says Vesalius plans to change its ticker to VLAB.
Funding Vesalius’s Expansion Plans
The financing gives Vesalius capital to pursue its stated plans to add sales capacity and enter new markets. Those steps could broaden the reach of its provider network and the services offered through its platform, though the company has not disclosed specific markets, launch dates or targets in the supplied report.
Spevak’s participation also links the fundraising to an executive with experience leading a consumer-focused fitness and wellness business. That may draw attention from investors and industry participants to Vesalius’s growth strategy, but the financing alone does not establish that the company will achieve its expansion goals or that the investor group will take an operational role.
Vesalius operates in a sector involving healthcare providers and services described as longevity-focused. Its planned growth therefore has business relevance beyond a single capital raise: it will test whether the company can build a larger provider network and deliver its platform across additional markets. The source does not report clinical results, regulatory clearances for specific offerings, or evidence that the platform improves health outcomes.
Products Worth Considering
Garmin Venu 4 GPS Fitness Smartwatch, 45 mm, Black Silicone
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
Spevak’s Move Into Longevity
The investment comes as Spevak remains chairman of Equinox Group after stepping down as its chief executive. Athletech News reported that former Anheuser-Busch CEO Brendan Whitworth took over as Equinox CEO the week before its story. Spevak’s Equinox tenure included the company’s expansion from traditional fitness into a broader luxury wellness offering, including its Optimize membership, which combines personal training, recovery services and health assessments.
The report frames the Vesalius financing as another move into the longevity sector for Spevak. It says an investor group he organized led the round; it does not identify all members of that group or give details about the amount invested by Spevak personally. Vesalius was formerly known as Sweet Earth Holdings Corporation, according to the source.
The proposed ticker change from SE to VLAB is described as a plan, not a completed exchange change. The supplied report does not give a date for the change or explain whether it depends on any further approvals or filings.
“I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade.”
— Harvey Spevak, Equinox Group chairman
Expansion Details Still Undisclosed
The announcement, as reported by Athletech News, does not identify the new markets Vesalius intends to enter, give a timetable for expansion or set measurable sales or provider-network targets. It also does not explain how the proceeds will be divided among hiring, market entry and platform development.
The source does not disclose the investor group’s full membership, Spevak’s personal contribution, or any governance rights attached to the investment. It also gives no update on the planned ticker change, and does not state whether investors have exercised any warrants.
Vesalius’s platform includes offerings in healthcare and wellness, but the report does not detail the regulatory status, clinical evidence or availability of each service in different jurisdictions. The company’s stated plans should not be read as proof that expansion has occurred or that its offerings produce particular health outcomes.
Vesalius’s Next Growth Milestones
The next developments to watch are Vesalius’s sales-team expansion, any announced market launches and progress in growing its network of licensed healthcare providers. The company has said the funding will support those efforts, but the supplied report gives no schedule or interim milestones.
Investors may also follow any filings or company announcements about the financing, including details of warrant issuance and any exercise activity, as well as confirmation of the planned change from ticker SE to VLAB. Until Vesalius provides further details, the scope and pace of its expansion remain unknown.
Key Questions
How much did Vesalius Longevity Labs raise?
Vesalius raised nearly $6.5 million in gross proceeds by selling approximately 6.2 million units at $1.05 each, according to Athletech News.
Who led the financing?
The round was led by an investor group organized by Harvey Spevak, chairman of Equinox Group. The supplied report does not name every member of the group or state Spevak’s personal investment amount.
How does Vesalius plan to use the funds?
The company says the proceeds will support sales-team expansion, entry into new markets and growth of its platform for licensed healthcare providers. It has not published a detailed budget or timetable.
What are the warrants included in the financing?
The transaction includes warrants allowing investors to buy additional shares at $2.25 per share over the next two years. The report does not say whether any warrants have been exercised.
What ticker does Vesalius trade under?
The company trades on the Canadian Securities Exchange as SE. It plans to change its ticker to VLAB, but the supplied report does not give a date for that change.
Source: athletechnews.com
![A Walkable ASCII Cyberpunk City In One HTML File [Video]](https://massageloungepro.com/wp-content/uploads/2026/09/a-walkable-ascii-cyberpunk-city-in-one-html-file-video-featured-560x300.jpg)
